论文部分内容阅读
目的 探讨P5 3和P2 1蛋白在鼻咽癌 (NPC)、癌旁组织和鼻咽慢性炎症中表达的差异 ,及其与肿瘤生物学行为的关系。材料与方法 首程放疗前的NPC病人 10 0例 ,癌旁组织和鼻咽慢性炎症对照组各 2 0例 ,用SP法进行P5 3和P2 1蛋白免疫组化染色 ,P5 3阳性细胞的标准为 :癌巢内肿瘤细胞核有棕色沉着的细胞 ;P2 1阳性细胞的标准为 :癌巢内肿瘤细胞浆有棕色沉着的细胞。结果 在鼻咽癌、癌旁组织和鼻咽慢性炎症组织中 ,P5 3蛋白的阳性率分别为 :78.0 %、3 5 .0 %和 0 .0 % ,P =0 .0 0 1;P2 1蛋白的阳性率分别为 :83 .0 %、75 .0 %和 65 .0 % ,P =0 .170。在鼻咽癌原发灶早期 (T1 + 2 )和晚期 (T3+ 4)、颈结阴性和阳性及临床早期 (Ⅰ +Ⅱ )和临床晚期 (Ⅲ +Ⅳ )各组中 ,P5 3蛋白和P2 1蛋白的阳性率均无差异 (P >0 .0 5 )。结论 P5 3基因的突变与鼻咽癌的发生有一定的关系 ,P5 3蛋白可能是鼻咽癌癌前病变的指标 ;P2 1基因的突变可能与鼻咽癌的发生无明显的关系。P5 3蛋白和P2 1蛋白的阳性率与鼻咽癌原发灶的早晚、颈结转移、和临床分期无关
Objective To investigate the difference of P53 and P2 1 protein expressions in nasopharyngeal carcinoma (NPC), pericarcinoma tissues and chronic inflammation of nasopharynx, and their relationship with tumor biological behavior. Materials and Methods 10 cases of NPC patients before radiotherapy, 20 cases of adjacent non-cancerous tissues and 20 cases of chronic nasopharyngeal inflammation were examined by SP immunohistochemical staining for P53 and P2 1, and the standard of P5 3 positive cells As follows: cancer nest tumor cell nucleus with brown cells; P2 1 positive cells in the standard: cancer nest tumor cells with brown cells. Results The positive rates of P53 protein in nasopharyngeal carcinoma, pericarcinoma tissues and chronic nasopharyngeal tissues were 78.0%, 35.0% and 0.0% respectively, P = 0.001. P2 1 The positive rates of protein were 83.0%, 75.0% and 65.0% respectively, P = 0.701. In the early stage (T1 + 2) and the late stage (T3 + 4) of nasopharyngeal carcinoma, the negative and positive cervical nodes and the early stage of clinical (stage I + Ⅱ) and the advanced stage of clinical stage (Ⅲ + Ⅳ), P53 protein and P2 1 protein positive rate no difference (P> 0.05). Conclusion The mutation of P53 gene has a certain relationship with the occurrence of NPC. P53 protein may be an indicator of precancerous lesions of nasopharyngeal carcinoma. The mutation of P2 1 may not be associated with the occurrence of NPC. The positive rate of P53 protein and P2 1 protein was not related to the early or late nasopharyngeal carcinoma, neck metastasis, and clinical stage